Baxter International Inc. vs. Boston Scientific Corp.
Boston Scientific Corp. (BSX) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| BAX | BSX | |
|---|---|---|
| Market Cap | $11.90 billion | $63.11 billion |
| Revenue (TTM) | $11.47 billion | $21.00 billion |
| Net Income (TTM) | $-1,063,000,000 | $3.67 billion |
BSX leads on 3 of 3 size & scale factors.
Valuation
| BAX | BSX | |
|---|---|---|
| P/E Ratio | — | 17.55 |
| Price / Book | 1.93 | 2.51 |
| Price / Sales | 1.04 | 3.01 |
BAX leads on 2 of 2 valuation factors.
Profitability
| BAX | BSX | |
|---|---|---|
| Net Margin | -9.27% | 17.47% |
| Return on Equity | -17.20% | 14.58% |
BSX leads on 2 of 2 profitability factors.
Dividend
| BAX | BSX | |
|---|---|---|
| Dividend Yield | 0.18% | — |
BAX and BSX split the dividend factors evenly.
Risk & Sentiment
| BAX | BSX | |
|---|---|---|
| Short Interest | 1.03% | 0.72% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BAX overview, BAX financials, BSX overview, BSX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.